{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:50:40Z","timestamp":1792716640028,"version":"4.5.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"\n Importance<\/jats:title>\n Migraine and major depressive disorder are frequently comorbid; however, evidence evaluating the efficacy of preventive migraine therapy in patients with both diseases is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n The UNITE study was a double-blind, placebo-controlled, parallel-group, randomized clinical trial consisting of a 4-week screening period, 12-week double-blind period, and 12-week open-label extension (OLE), conducted between July 9, 2020, and August 31, 2022. The trial was conducted at 55 centers across 12 countries. Eligible patients were adults with episodic migraine (EM) or chronic migraine (CM), history of major depressive disorder according to\n Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n (Fifth Edition) criteria for 12 or more months before screening, and active symptoms of depression (9-item Patient Health Questionnaire score of 10 or more) at screening.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 1:1 to receive monthly fremanezumab (225 mg) or matched placebo. All patients in the OLE received quarterly fremanezumab (675 mg).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the mean change from baseline in monthly migraine days during the 12-week double-blind period.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 540 patients screened for the study, 353 patients (mean [SD] age, 42.9 [12.3] years; 310 female [88%]; EM, 48%; CM, 52%) were eligible and randomized to receive fremanezumab (n\u2009=\u2009175) or placebo (n\u2009=\u2009178). Mean (SE) change from baseline in monthly migraine days during the 12-week double-blind period was \u22125.1 (0.50; 95% CI, \u22126.09 to \u22124.13) for fremanezumab and \u22122.9 (0.49; 95% CI, \u22123.89 to \u22121.96) for placebo (\n P<\/jats:italic>\n \u2009&amp;lt;.001). Mean (SE) change from baseline in the Hamilton Depression Rating Scale\u201317 Items score at week 8 was \u22126.0 (0.55; 95% CI, \u22127.10 to \u22124.95) for fremanezumab and \u22124.6 (0.54; 95% CI, \u22125.66 to \u22123.55) for placebo (least squares mean [SE] difference: \u22121.4 [0.61]; 95% CI, \u22122.61 to \u22120.22;\n P<\/jats:italic>\n \u2009=\u2009.02). Adverse events were consistent with other fremanezumab trials. Results were maintained throughout the OLE.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Treatment with fremanezumab compared with placebo resulted in significant reductions in monthly migraine days and depressive symptoms. No new safety concerns were observed. To the authors\u2019 knowledge, this was the first placebo-controlled, randomized clinical trial, specifically designed to assess patients with migraine and comorbid depressive disorder, to demonstrate significant improvements in migraine and depressive symptoms with a single pharmacological intervention.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04041284<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.0806","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:00:45Z","timestamp":1746442845000},"page":"560","source":"Crossref","is-referenced-by-count":28,"title":["Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder"],"prefix":"10.1001","volume":"82","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[{"name":"Departments of Neurology, Psychiatry and Behavioral Sciences, and the Montefiore Headache Center, Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Ramirez Campos","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc, West Chester, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipi","family":"Roth-Ben Arie","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Galic","sequence":"additional","affiliation":[{"name":"Teva-Pharma, Produtos Farmac\u00eauticos, Lda, Porto Salvo, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Mitsikostas","sequence":"additional","affiliation":[{"name":"Department of First Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Denysenko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania"},{"name":"Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Braeburn Inc, Plymouth Meeting, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi250019r1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0972753120929563","article-title":"Migraine disability, quality of life, and its predictors.","volume":"27","author":"Pradeep","year":"2020","journal-title":"Ann Neurosci"},{"issue":"1","key":"noi250019r2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","article-title":"The impact of headache in Europe: principal results of the Eurolight project.","volume":"15","author":"Steiner","year":"2014","journal-title":"J Headache Pain"},{"issue":"5","key":"noi250019r3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5271\/sjweh.3583","article-title":"The relationship between chronic conditions and absenteeism and associated costs in Canada.","volume":"42","author":"Zhang","year":"2016","journal-title":"Scand J Work Environ Health"},{"issue":"1","key":"noi250019r4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","article-title":"Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the UK.","volume":"19","author":"Vo","year":"2018","journal-title":"J Headache Pain"},{"key":"noi250019r5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","article-title":"Impact of migraine on the family: perspective of people with migraine and their spouse\/domestic partner in the CaMEO study.","volume":"91","author":"Buse","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"noi250019r6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/head.13342","article-title":"Identifying natural subgroups of migraine based on comorbidity and concomitant condition profiles: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"issue":"8","key":"noi250019r7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/head.13914","article-title":"The effect of psychiatric comorbidities on headache-related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache"},{"issue":"7","key":"noi250019r8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities.","volume":"87","author":"Minen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"noi250019r9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","article-title":"Depression and risk of transformation of episodic to chronic migraine.","volume":"13","author":"Ashina","year":"2012","journal-title":"J Headache Pain"},{"issue":"5","key":"noi250019r10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: a population-based case-control study.","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"noi250019r11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1212\/WNL.54.2.308","article-title":"Headache and major depression: is the association specific to migraine?","volume":"54","author":"Breslau","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"noi250019r12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10194-010-0282-4","article-title":"Migraine and psychiatric comorbidity: a review of clinical findings.","volume":"12","author":"Antonaci","year":"2011","journal-title":"J Headache Pain"},{"issue":"4","key":"noi250019r13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1468-2982.1999.019004211.x","article-title":"Comorbidity of headache and depressive disorders.","volume":"19","author":"Mitsikostas","year":"1999","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250019r14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the Migraine in America Symptoms and Treatment (MAST) study.","volume":"21","author":"Buse","year":"2020","journal-title":"J Headache Pain"},{"issue":"7","key":"noi250019r15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1526-4610.1994.hed3407387.x","article-title":"Joint 1994 Wolff Award presentation. migraine and major depression: a longitudinal study.","volume":"34","author":"Breslau","year":"1994","journal-title":"Headache"},{"key":"noi250019r16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1143060","article-title":"The relationship between major depression and migraine: a bidirectional 2-sample mendelian randomization study.","volume":"14","author":"Lv","year":"2023","journal-title":"Front Neurol"},{"issue":"4","key":"noi250019r17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1526-4610.2007.00760.x","article-title":"Pharmacological approaches to managing migraine and associated comorbidities\u2013clinical considerations for monotherapy versus polytherapy.","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"noi250019r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107151","article-title":"Venlafaxine can reduce the migraine attacks as well as amitriptyline: a noninferiority randomized trial.","volume":"214","author":"Hedayat","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"issue":"22","key":"noi250019r19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006989","article-title":"Tricyclic antidepressants for preventing migraine in adults.","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"noi250019r26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"10203","key":"noi250019r27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to 4 migraine preventive medication classes (FOCUS): a randomized, double-blind, placebo-controlled, phase 3b trial.","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"noi250019r28","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine.","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"noi250019r29","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/head.13997","article-title":"Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from HALO CM study.","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache"},{"issue":"4","key":"noi250019r30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study.","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi250019r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd Edition.","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalagia"},{"issue":"9","key":"noi250019r33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"2","key":"noi250019r34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1533317514539378","article-title":"Standardized Mini-Mental State Examination scores and verbal memory performance at a memory center: implications for cognitive screening.","volume":"30","author":"Lacy","year":"2015","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"noi250019r36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi250019r37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.873693","article-title":"A randomized clinical trial comparing 2 treatment strategies, evaluating the meaningfulness of HAM-D Rating Scale in patients with major depressive disorder.","volume":"13","author":"Asghar","year":"2022","journal-title":"Front Psychiatry"},{"issue":"2","key":"noi250019r38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","article-title":"Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression.","volume":"27","author":"Hengartner","year":"2022","journal-title":"BMJ Evid Based Med"},{"issue":"18","key":"noi250019r39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"key":"noi250019r40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jad.2020.11.066","article-title":"Meaningful change in depression symptoms assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-\u00c5sberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in 2, randomized, double-blind, active-controlled trials of esketamine nasal spray combined with a new oral antidepressant.","volume":"281","author":"Hudgens","year":"2021","journal-title":"J Affect Disord"},{"issue":"3","key":"noi250019r41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1503\/cmaj.112004","article-title":"Enhancing the clinical utility of depression screening.","volume":"184","author":"Kroenke","year":"2012","journal-title":"CMAJ"},{"issue":"3","key":"noi250019r42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jad.2012.08.026","article-title":"Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials.","volume":"145","author":"Boessen","year":"2013","journal-title":"J Affect Disord"},{"key":"noi250019r44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/NDT.S358367","article-title":"Use of Clinical Global Impressions-Severity (CGI-S) to assess response to antidepressant treatment in patients with treatment-resistant depression.","volume":"18","author":"Morrens","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"noi250019r45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0333102412449933","article-title":"Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache.","volume":"32","author":"Castien","year":"2012","journal-title":"Cephalalgia"},{"issue":"7","key":"noi250019r47","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","article-title":"A scoping review and meta-analyses of anti-CGRP monoclonal antibodies: predicting response.","volume":"16","author":"Hong","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"noi250019r48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/NDT.S216389","article-title":"Inflammation and coronary heart disease risk in patients with depression in China mainland: a cross-sectional study.","volume":"16","author":"Zhou","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"noi250019r49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0304-3940(94)90782-X","article-title":"Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients\u2014a possible trait marker of major depressive disorder.","volume":"182","author":"Math\u00e9","year":"1994","journal-title":"Neurosci Lett"},{"issue":"2","key":"noi250019r50","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16106","article-title":"Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine.","volume":"31","author":"de Vries Lentsch","year":"2024","journal-title":"Eur J Neurol"},{"key":"noi250019r51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.physbeh.2014.11.049","article-title":"The role of calcitonin gene-related peptide in post-stroke depression in chronic mild stress-treated ischemic rats.","volume":"139","author":"Shao","year":"2015","journal-title":"Physiol Behav"},{"issue":"12","key":"noi250019r52","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/mp.2012.136","article-title":"Gestational environment programs adult depressionlike behavior through methylation of the calcitonin gene-related peptide gene.","volume":"18","author":"Jiao","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"7","key":"noi250019r53","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/head.14177","article-title":"Treatment of medication overuse headache: effect and predictors after 1 year\u2014a randomized controlled trial.","volume":"61","author":"Carlsen","year":"2021","journal-title":"Headache"},{"issue":"7","key":"noi250019r54","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1111\/jcmm.14390","article-title":"The exploration of mechanisms of comorbidity between migraine and depression.","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"12","key":"noi250019r55","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","article-title":"Risk factors for migraine disease progression: a narrative review for a patient-centered approach.","volume":"270","author":"Lipton","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"noi250019r56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0333102410372427","article-title":"Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.","volume":"31","author":"Lipton","year":"2011","journal-title":"Cephalalgia"},{"issue":"5","key":"noi250019r57","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis.","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"issue":"10","key":"noi250019r58","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40263-019-00662-y","article-title":"Meta-analysis of placebo response in adult antidepressant trials.","volume":"33","author":"Li","year":"2019","journal-title":"CNS Drugs"},{"issue":"9","key":"noi250019r59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis.","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"noi250019r60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","article-title":"The prevalence and impact of migraine and severe headache in the US: figures and trends from government health studies.","volume":"58","author":"Burch","year":"2018","journal-title":"Headache"},{"key":"noi250019r31","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"2013","edition":"5th ed"},{"key":"noi250019r20","unstructured":"Medicines.org.uk. Ajovy (fremanezumab) 225 mg solution for injection in prefilled syringe. Accessed May 1, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/10386\/smpc\/print"},{"key":"noi250019r21","unstructured":"Medicines.org.uk. Emgality 120 mg solution for injection in prefilled pen. Accessed May 1, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/10478\/smpc\/print"},{"key":"noi250019r22","unstructured":"Medicines.org.uk. Aimovig 70 mg solution for injection in prefilled pen. Accessed May 1, 2024.https:\/\/www.medicines.org.uk\/emc\/product\/9380\/smpc\/print"},{"key":"noi250019r23","unstructured":"Medicines.org.uk. Vyepti 100 mg concentrate for solution for infusion. Accessed May 1, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/13243\/smpc\/print"},{"key":"noi250019r24","unstructured":"Food and Drug Administration (FDA). AJOVY (fremanezumab). Accessed May 1, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761089s013lbl.pdf"},{"key":"noi250019r25","unstructured":"European Medicines Agency (EMA). AJOVY (fremanezumab). Accessed May 1, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy"},{"key":"noi250019r35","unstructured":"National Institute for Health and Care Excellence (NICE). Depression: how should I assess a person with suspected depression? Accessed December 12, 2024. https:\/\/cks.nice.org.uk\/topics\/depression\/diagnosis\/assessment\/"},{"key":"noi250019r43","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (3rd ed). Accessed December 12, 2024. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"noi250019r46","unstructured":"US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Major depressive disorder: developing drugs for treatment guidance for industry. Accessed December 12, 2024. https:\/\/www.fda.gov\/media\/113988\/download"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2833452\/jamaneurology_lipton_2025_oi_250019_1750886115.48303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:00:46Z","timestamp":1751281246000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2833452"}},"subtitle":["The UNITE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.0806","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}